ReAlta Life Sciences, Inc.
6 clinical trials · Sponsor
◉ Watch ReAlta Life Sciences, Inc.
| Record | Firm | Date |
|---|---|---|
| Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (NCT06343792) | ReAlta Life Sciences, Inc. | 2024-08-31 |
| Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (NCT06175065) | ReAlta Life Sciences, Inc. | 2024-01-25 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia (NCT05778188) | ReAlta Life Sciences, Inc. | 2023-07-27 |
| A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS (NCT05351671) | ReAlta Life Sciences, Inc. | 2022-05-23 |
| A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure (NCT04574869) | ReAlta Life Sciences, Inc. | 2021-01-01 |
Track ReAlta Life Sciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.